Associations between retinal thickness and background factors in eyes without retinal diseases
- PMID: 40596439
- PMCID: PMC12215744
- DOI: 10.1038/s41598-025-06863-4
Associations between retinal thickness and background factors in eyes without retinal diseases
Abstract
Retinal thickness measured using optical coherence tomography (OCT) is a major parameter to evaluate retinal diseases. However, it may be influenced by systemic factors. We retrospectively analyzed OCT images and blood sample data from 266 participants (49.1 ± 10.5 years) including 181 (68.0%) males who underwent medical checkups at Fujita Medical Innovation Center, Tokyo. Those with retinal pathological findings were excluded. Males had thicker retinas in the center and inner circles of Early Treatment Diabetic Retinopathy Study grid (P < 0.01 for all). Mean thicknesses of the superior areas were greater than those of the inferior areas in inner and outer circles (P < 0.01 for both). However, there were eyes with thicker inner inferior areas (72 eyes, 27.1%), which was observed more frequently in males (P = 0.018). Thicker retinas were associated with lower hemoglobin A1c levels in the center (P = 0.012), and inner temporal (P = 0.042) and inferior (P = 0.047) areas; lower creatinine levels in the inner temporal (P = 0.002), superior (P = 0.026), and inferior (P < 0.001) areas; and higher high-density lipoprotein cholesterol levels in the inner nasal (P = 0.029) and inferior (P = 0.029) areas after adjusting for age and sex. These results may be kept in mind in evaluating OCT data during clinical practice and future clinical trials, although further studies are warranted.
Keywords: Blood test; Retina; Sex; Thickness.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics declarations: This retrospective study adhered to the tenets of the Declaration of Helsinki, was approved by the Fujita Health University Ethics Committee (approval number: HM23-276). Consent to participate/Consent to publish: This retrospective study was approved by the Fujita Health University Ethics Committee (approval number: HM23-276).
Similar articles
-
Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008081. doi: 10.1002/14651858.CD008081.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2015 Jan 07;1:CD008081. doi: 10.1002/14651858.CD008081.pub3. PMID: 21735421 Updated.
-
Longitudinal Assessment of Ocular Biomarkers in Individuals With Gulf War Illness Symptoms.Mil Med. 2025 Jun 30;190(7-8):e1670-e1678. doi: 10.1093/milmed/usae457. Mil Med. 2025. PMID: 39361156 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery.Cochrane Database Syst Rev. 2016 Nov 1;11(11):CD006683. doi: 10.1002/14651858.CD006683.pub3. Cochrane Database Syst Rev. 2016. PMID: 27801522 Free PMC article.
-
Association of serum adiponectin and leptin levels with inner retinal thickness among individuals with or without elevated HbA1c.Sci Rep. 2025 Mar 12;15(1):8498. doi: 10.1038/s41598-025-93562-9. Sci Rep. 2025. PMID: 40075217 Free PMC article.
References
-
- Heier, J. S. et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet402, 1434–1448. 10.1016/S0140-6736(23)01520-9 (2023). - PubMed
-
- Khanani, A. M. et al. Efficacy and safety of Avacincaptad Pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet402, 1449–1458. 10.1016/S0140-6736(23)01583-0 (2023). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical